In vitro activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM)

Novel antimicrobials are needed to treat rising nontuberculous mycobacteria (NTM) infections. Using standard broth microdilution methods, 68 NTM isolates were tested against gepotidacin, a new, first-in-class, oral triazaacenaphthylene bacterial topoisomerase inhibitor. MICs varied (0.25 to >64 µg/mL) with the lowest being M. fortuitum complex (0.25–8 µg/mL), M. mucogenicum complex (1–2 µg/mL), M. kansasii (0.25–8 µg/mL), and M. marinum (4–16 µg/mL). Testing greater numbers of some species is suggested to better understand gepotidacin activity against NTM.